{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T00:39:39Z","timestamp":1794443979160,"version":"4.9.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020955","name":"GlaxoSmithKline Biologicals SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.vaccine.2025.126953","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T03:42:00Z","timestamp":1741059720000},"page":"126953","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Identification of immunogenic outer membrane vesicle vaccine antigen components using a meningococcal protein microarray"],"prefix":"10.1016","volume":"53","author":[{"given":"F.","family":"Ramirez-Bencomo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Thistlethwaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Viviani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bartolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pizza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Biolchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Muzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Delany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Awanye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.M.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Borrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.P.","family":"Derrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.126953_bb0005","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","article-title":"Meningococcal carriage by age: a systematic review and meta-analysis","volume":"10","author":"Christensen","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.126953_bb0010","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41579-019-0282-6","article-title":"Neisseria meningitidis: using genomics to understand diversity, evolution and pathogenesis","volume":"18","author":"Caugant","year":"2020","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2025.126953_bb0015","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0035-9203(99)90106-2","article-title":"Meningococcal meningitis in Africa","volume":"93","author":"Manson","year":"1999","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2025.126953_bb0020","series-title":"The global meningococcal initiative: Global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection","author":"Borrow","year":"2017"},{"key":"10.1016\/j.vaccine.2025.126953_bb0025","first-page":"323","article-title":"A perspective on the novel pentavalent Men5CV (NmCV-5) meningitis vaccine and Nigeria\u2019s pioneering rollout campaign","volume":"32","author":"Ukoaka","year":"2024","journal-title":"Infez Med"},{"key":"10.1016\/j.vaccine.2025.126953_bb0030","first-page":"8","article-title":"Vaccines against meningococcal diseases","author":"Pizza","year":"2020","journal-title":"Microorganisms"},{"key":"10.1016\/j.vaccine.2025.126953_bb0035","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/0140-6736(91)91961-S","article-title":"Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway","volume":"338","author":"Bjune","year":"1991","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.vaccine.2025.126953_bb0040","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/j.vaccine.2005.01.063","article-title":"MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain","volume":"23","author":"Oster","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126953_bb0045","doi-asserted-by":"crossref","first-page":"751","DOI":"10.3389\/fimmu.2019.00751","article-title":"The development of a vaccine against meningococcus B using reverse vaccinology","volume":"10","author":"Masignani","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.126953_bb0050","doi-asserted-by":"crossref","first-page":"10834","DOI":"10.1073\/pnas.0603940103","article-title":"A universal vaccine for serogroup B meningococcus","volume":"103","author":"Giuliani","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2025.126953_bb0055","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1126\/science.287.5459.1816","article-title":"Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing","volume":"287","author":"Pizza","year":"2000","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.vaccine.2025.126953_bb0060","doi-asserted-by":"crossref","unstructured":"Del Tordello E, Rappuoli R, Delany I. Reverse vaccinology. Human Vaccines2017. p. 65\u201386.","DOI":"10.1016\/B978-0-12-802302-0.00002-9"},{"key":"10.1016\/j.vaccine.2025.126953_bb0065","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S1473-3099(20)30600-9","article-title":"Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trial","volume":"21","author":"Davis","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.126953_bb0070","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1186\/s12879-021-06906-x","article-title":"A re-assessment of 4CMenB vaccine effectiveness against serogroup B invasive meningococcal disease in England based on an incidence model","volume":"21","author":"Argante","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2025.126953_bb0075","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41541-023-00651-9","article-title":"OpcA and PorB are novel bactericidal antigens of the 4CMenB vaccine in mice and humans","volume":"8","author":"Viviani","year":"2023","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2025.126953_bb0080","doi-asserted-by":"crossref","first-page":"6843","DOI":"10.1038\/s41598-019-43139-0","article-title":"Immunogenicity profiling of protein antigens from capsular group B Neisseria meningitidis","volume":"9","author":"Awanye","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2025.126953_bb0085","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jinf.2015.05.006","article-title":"A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: a phase I clinical trial","volume":"71","author":"Marsay","year":"2015","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2025.126953_bb0090","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1016\/j.vaccine.2022.05.032","article-title":"Application of a Neisseria meningitidis antigen microarray to identify candidate vaccine proteins from a human phase I clinical trial","volume":"40","author":"Chang","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126953_bb0095","doi-asserted-by":"crossref","first-page":"4994","DOI":"10.1038\/s41467-020-18791-0","article-title":"Immunological fingerprint of 4CMenB recombinant antigens via protein microarray reveals key immunosignatures correlating with bactericidal activity","volume":"11","author":"Bartolini","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2025.126953_bb0100","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1016\/j.vaccine.2015.05.027","article-title":"Safety and immunogenicity of a four-component meningococcal group B vaccine (4CMenB) and a quadrivalent meningococcal group ACWY conjugate vaccine administered concomitantly in healthy laboratory workers","volume":"33","author":"Findlow","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126953_bb0105","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/978-1-61779-346-2_6","article-title":"Expression, purification, and crystallization of neisserial outer membrane proteins","volume":"799","author":"Saleem","year":"2012","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2025.126953_bb0110","first-page":"9","article-title":"Visualizing data using t-SNE","author":"Van der Maaten","year":"2008","journal-title":"J Mach Learn Res"},{"key":"10.1016\/j.vaccine.2025.126953_bb0115","first-page":"3221","article-title":"Accelerating t-SNE using tree-based algorithms","volume":"15","author":"van der Maaten","year":"2014","journal-title":"J Mach Learn Res"},{"key":"10.1016\/j.vaccine.2025.126953_bb0120","unstructured":"Kassambara A, Mundt F. Extract and Visualize the Results of Multivariate Data Analyses [R package factoextra version 1.0.7]. 2020."},{"key":"10.1016\/j.vaccine.2025.126953_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v028.i05","article-title":"Building predictive models inRUsing thecaretPackage","volume":"28","author":"Kuhn","year":"2008","journal-title":"J Stat Softw"},{"key":"10.1016\/j.vaccine.2025.126953_bb0130","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/cem.2736","article-title":"Comparison of the variable importance in projection (VIP) and of the selectivity ratio (SR) methods for variable selection and interpretation","volume":"29","author":"Farr\u00e9s","year":"2015","journal-title":"J Chemometr"},{"key":"10.1016\/j.vaccine.2025.126953_bb0135","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1016\/j.vaccine.2013.03.065","article-title":"Evaluation of vaccine-induced antibody responses: impact of new technologies","volume":"31","author":"Zaccaro","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126953_bb0140","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1016\/j.vaccine.2020.01.038","article-title":"Deletion of major porins from meningococcal outer membrane vesicle vaccines enhances reactivity against heterologous serogroup B Neisseria meningitidis strains","volume":"38","author":"Matthias","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126953_bb0145","first-page":"22","article-title":"Predicted proteins of Neisseria meningitidis as potential vaccine candidates: from in silico analyses to experimental corroboration","volume":"29","author":"Garc\u00eda","year":"2012","journal-title":"Biotecnolog\u00eda Aplicada"},{"key":"10.1016\/j.vaccine.2025.126953_bb0150","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1080\/14760584.2021.1940144","article-title":"Correlates of protection for meningococcal surface protein vaccines: lessons from the past","volume":"21","author":"Findlow","year":"2022","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2025.126953_bb0155","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1086\/656741","article-title":"Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy","volume":"51","author":"Findlow","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.126953_bb0160","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1097\/INF.0b013e3181f59f6d","article-title":"Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial","volume":"29","author":"Snape","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2025.126953_bb0165","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1080\/21645515.2018.1537756","article-title":"Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules","volume":"15","author":"Biolchi","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2025.126953_bb0170","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2206433","article-title":"Effectiveness of a meningococcal group B vaccine (4CMenB) in children","volume":"388","author":"Castilla","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.126953_bb0175","doi-asserted-by":"crossref","first-page":"e1661","DOI":"10.1093\/cid\/ciaa1244","article-title":"First real-world evidence of meningococcal group B vaccine, 4CMenB, protection against meningococcal group W disease: prospective enhanced National Surveillance, England","volume":"73","author":"Ladhani","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2025.126953_bb0180","doi-asserted-by":"crossref","first-page":"B87","DOI":"10.1016\/j.vaccine.2012.01.033","article-title":"The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens","volume":"30","author":"Serruto","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126953_bb0185","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.vaccine.2014.01.011","article-title":"Quantification by LC-MS(E) of outer membrane vesicle proteins of the Bexsero(R) vaccine","volume":"32","author":"Tani","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126953_bb0190","doi-asserted-by":"crossref","DOI":"10.1128\/msphere.00674-21","article-title":"Human B Cell Responses to Dominant and Subdominant Antigens Induced by a Meningococcal Outer Membrane Vesicle Vaccine in a Phase I Trial","volume":"7","author":"Rollier","year":"2022","journal-title":"mSphere"},{"key":"10.1016\/j.vaccine.2025.126953_bb0195","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1128\/IAI.67.5.2406-2413.1999","article-title":"Structural and evolutionary inference from molecular variation in Neisseria porins","volume":"67","author":"Derrick","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2025.126953_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056746","article-title":"Use of a molecular decoy to segregate transport from antigenicity in the FrpB iron transporter from Neisseria meningitidis","volume":"8","author":"Saleem","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2025.126953_bb0205","doi-asserted-by":"crossref","first-page":"6712","DOI":"10.1038\/s41467-024-51053-x","article-title":"Profiling IgG and IgA antibody responses during vaccination and infection in a high-risk gonorrhoea population","volume":"15","author":"Stejskal","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2025.126953_bb0210","first-page":"482","article-title":"Lipopolysaccharide-induced immunological tolerance in monocyte-derived dendritic cells","volume":"2","author":"Mbongue","year":"2022","journal-title":"Immunology"},{"key":"10.1016\/j.vaccine.2025.126953_bb0215","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1128\/IAI.72.1.371-380.2004","article-title":"Neisseria meningitidis lipooligosaccharide structure-dependent activation of the macrophage CD14\/toll-like receptor 4 pathway","volume":"72","author":"Zughaier","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2025.126953_bb0220","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/14760584.2022.2009803","article-title":"GMMA as a \u2018plug and play\u2019 technology to tackle infectious disease to improve global health: context and perspectives for the future","volume":"21","author":"Piccioli","year":"2022","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2025.126953_bb0225","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.867119","article-title":"Biological Nanoparticles in Vaccine Development","volume":"10","author":"Curley","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.vaccine.2025.126953_bb0230","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.4049\/jimmunol.174.6.3545","article-title":"Neisserial porin-induced dendritic cell activation is MyD88 and TLR2 dependent","volume":"174","author":"Singleton","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2025.126953_bb0235","doi-asserted-by":"crossref","first-page":"5590","DOI":"10.1128\/IAI.71.10.5590-5597.2003","article-title":"Activation of human dendritic cells is modulated by components of the outer membranes of Neisseria meningitidis","volume":"71","author":"Al-Bader","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2025.126953_bb0240","doi-asserted-by":"crossref","first-page":"5939","DOI":"10.1128\/IAI.00846-07","article-title":"Agonists of toll-like receptors 3, 4, 7, and 9 are candidates for use as adjuvants in an outer membrane vaccine against Neisseria meningitidis serogroup B","volume":"75","author":"Fransen","year":"2007","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2025.126953_bb0245","doi-asserted-by":"crossref","first-page":"5091","DOI":"10.1016\/j.vaccine.2005.06.001","article-title":"Well-defined and potent liposomal meningococcal B vaccines adjuvated with LPS derivatives","volume":"23","author":"Arigita","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126953_bb0250","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.1128\/IAI.69.10.5981-5990.2001","article-title":"Modification of lipid a biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity","volume":"69","author":"van der Ley","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2025.126953_bb0255","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1016\/j.vaccine.2010.05.014","article-title":"Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus","volume":"28","author":"Giuliani","year":"2010","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25002506?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25002506?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T06:25:10Z","timestamp":1745130310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25002506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":51,"alternative-id":["S0264410X25002506"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126953","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of immunogenic outer membrane vesicle vaccine antigen components using a meningococcal protein microarray","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126953","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126953"}}